{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:14:43Z","timestamp":1791983683976,"version":"4.4.0"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T00:00:00Z","timestamp":1553644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0567-3","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T16:58:17Z","timestamp":1553705897000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry"],"prefix":"10.1136","volume":"7","author":[{"given":"M.","family":"Fishman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-9187","authenticated-orcid":false,"given":"J. P.","family":"Dutcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. I.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. P.","family":"Miletello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Curti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hauke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Treisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. S.","family":"Tykodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,3,27]]},"reference":[{"issue":"Suppl 1","key":"567_CR1","first-page":"S55","volume":"6","author":"RI Fisher","year":"2000","unstructured":"Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Amer. 2000;6(Suppl 1):S55\u20137.","journal-title":"Cancer J Sci Amer"},{"issue":"Suppl 2","key":"567_CR2","first-page":"P225","volume":"3","author":"JI Clark","year":"2015","unstructured":"Clark JI, Morse MA, Wong MKK, McDermott DF, Kaufman HL, Daniels GA, et al. Durability of responses in patients with metastatic renal cell carcinoma treated with HD IL-2. JITC. 2015;3(Suppl 2):P225.","journal-title":"JITC"},{"key":"567_CR3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00262-016-1910-x","volume":"65","author":"A Alva","year":"2016","unstructured":"Alva A, Daniels GA, Wong MK, Kaufman H, Morse MA, McDermott DF, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016;65:1533\u201344.","journal-title":"Cancer Immunol Immunother"},{"key":"567_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00262-016-1854-1","volume":"65","author":"DD Stenehjem","year":"2016","unstructured":"Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, et al. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol Immunother. 2016;65:941\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"567_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1078-0432.CCR-14-1520","volume":"21","author":"DF McDermott","year":"2015","unstructured":"McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, et al. The high-dose aldesleukin \u201cselect\u201d trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21:561\u20138.","journal-title":"Clin Cancer Res"},{"key":"567_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clgc.2015.10.008","volume":"15","author":"JI Clark","year":"2017","unstructured":"Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, et al. Impact of sequencing targeted therapies with high-dose interleukin-2 immunotherapy: an analysis of outcome and survival of patients with metastatic renal cell carcinoma from an on-going observational IL-2 clinical trial. PROCLAIMSM. Clin Genitourin Cancer. 2017;15:31\u201341. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2015.10.008\n                    \n                  .","journal-title":"Clin Genitourin Cancer"},{"issue":"Suppl 2","key":"567_CR7","first-page":"87","volume":"5","author":"JI Clark","year":"2017","unstructured":"Clark JI, Curti B, Davis E, Kaufman H, Amin A, Alva A, et al. Long-term disease-free survival of melanoma and renal cell cancer patients following high-dose interleukin-2. JITC. 2017;5(Suppl 2):87 P319.","journal-title":"JITC"},{"key":"567_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40425-017-0307-5","volume":"5","author":"B Curti","year":"2017","unstructured":"Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, et al. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. JITC. 2017;5:102. \n                    https:\/\/doi.org\/10.1186\/s40425-017-0307-5\n                    \n                  .","journal-title":"JITC"},{"key":"567_CR9","first-page":"26","volume":"2","author":"JP Dutcher","year":"2014","unstructured":"Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder J, Atkins MB. High dose Interleukin-2 (Aldesleukin) \u2013 expert consensus on best management practices \u2013 2014. JITC. 2014;2:26.","journal-title":"JITC"},{"issue":"15S","key":"567_CR10","first-page":"260s","volume":"36","author":"M Fishman","year":"2018","unstructured":"Fishman M, Clark JI, Alva A, Curti B, Agarwal N, Hauke R, et al. Overall survival by clinical risk category for high dose Interleukin-2 treated metastatic renal cell cancer: data from PROCLAIMSM. J Clin Oncol. 2018;36(15S):260s.","journal-title":"J Clin Oncol"},{"key":"567_CR11","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530\u201340.","journal-title":"J Clin Oncol"},{"key":"567_CR12","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.2000.18.9.1928","volume":"18","author":"RJ Motzer","year":"2000","unstructured":"Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz E. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:1928\u201335.","journal-title":"J Clin Oncol"},{"key":"567_CR13","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-11-0553","volume":"17","author":"J Manola","year":"2011","unstructured":"Manola J, Royston P, Elson P, McCormack JB, Mazumdar M, Negrier S, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res. 2011;17:5443\u201350.","journal-title":"Clin Cancer Res"},{"key":"567_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/oxfordjournals.annonc.a058239","volume":"3","author":"PA Palmer","year":"1992","unstructured":"Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 1992;3:475\u201380.","journal-title":"Ann Oncol"},{"key":"567_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/annonc\/mdf257","volume":"13","author":"S Negrier","year":"2002","unstructured":"Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Fran\u00e7ais d\u2019Immunoth\u00e9rapie. Ann Oncol. 2002;13:1460\u20138.","journal-title":"Ann Oncol"},{"key":"567_CR16","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794\u20139.","journal-title":"J Clin Oncol"},{"key":"567_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DY Heng","year":"2013","unstructured":"Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the international metastatic renal \u2013cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141\u20138.","journal-title":"Lancet Oncol"},{"key":"567_CR18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren-Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"567_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/jpm4010052","volume":"4","author":"HL Kaufman","year":"2014","unstructured":"Kaufman HL, Wong MK, Daniels GA, McDermott DF, Aung S, Lowder J, Morse MA. The use of registries to improve cancer treatment: a national database for patients treated with interleukin-2 (IL-2). J Personalized Med. 2014;4:52\u201364.","journal-title":"J Personalized Med"},{"key":"567_CR20","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"issue":"Suppl 7S","key":"567_CR21","doi-asserted-by":"publisher","first-page":"abstr 542","DOI":"10.1200\/JCO.2019.37.7_suppl.542","volume":"37","author":"L Albiges","year":"2019","unstructured":"Albiges L, Negrier S, Dalban C, Chevreau C, Gravis G, Oudard S, et al. Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from NIVOREN GETUG AFU 26 study. J Clin Oncol. 2019;37(Suppl 7S):abstr 542.","journal-title":"J Clin Oncol"},{"key":"567_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2051-1426-2-20","volume":"2","author":"MK Wong","year":"2014","unstructured":"Wong MK, Kaufman HL, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. Commentary: Implementation of an interleukin-2 national registry: an opportunity to improve cancer outcomes. JITC. 2014;2:20. \n                    https:\/\/doi.org\/10.1186\/2051-1426-2-20\n                    \n                  .","journal-title":"JITC"},{"issue":"4","key":"567_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40425-016-0155-8","volume":"20","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, et al. A retrospective analysis of high dose interleukin-2 following ipilimumab in metastatic melanoma. JITC. 2016;20(4):52. \n                    https:\/\/doi.org\/10.1186\/s40425-016-0155-8\n                    \n                  .","journal-title":"JITC"},{"key":"567_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-019-0522-3","volume":"7","author":"EI Buchbinder","year":"2019","unstructured":"Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, et al. Therapy with high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. JITC. 2019;7:49. \n                    https:\/\/doi.org\/10.1186\/s40425-019-0522-3\n                    \n                  .","journal-title":"JITC"},{"key":"567_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","volume":"12","author":"AV Maker","year":"2005","unstructured":"Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin-2: a phase I\/II study. Ann Surg Oncol. 2005;12:1005\u201316.","journal-title":"Ann Surg Oncol"},{"key":"567_CR26","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","volume":"18","author":"PA Prieto","year":"2012","unstructured":"Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039\u201347.","journal-title":"Clin Cancer Res"},{"key":"567_CR27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/CJI.0b013e3181ecccad","volume":"33","author":"SE Finkelstein","year":"2010","unstructured":"Finkelstein SE, Carey T, Fricke I, Daohai Y, Goetz D, Gratz M, et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010;33:817\u201327.","journal-title":"J Immunother"},{"issue":"Suppl 7S","key":"567_CR28","doi-asserted-by":"publisher","first-page":"abstr 657","DOI":"10.1200\/JCO.2019.37.7_suppl.657","volume":"37","author":"J Chatzkel","year":"2019","unstructured":"Chatzkel J, Swank J, Ludlow S, Lombardi K, Croft C, Artigas Y, et al. Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer, a single center, single arm trial. J Clin Oncol. 2019;37(Suppl 7S):abstr 657.","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0567-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0567-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0567-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:47:21Z","timestamp":1601056041000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0567-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,27]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["567"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0567-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,27]]},"assertion":[{"value":"5 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This registry study was approved by the institutional review boards of the sites enrolling subjects, and all patients provided written, informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MF has received research funding from Eisai, Pfizer, Prometheus, Merck, Tracon, Eisai, Exelixis; JPD is a consultant for Prometheus Laboratories, and member of data safety and monitoring committees for BMS, Merck, Tracon, Amgen, Iovance, Eisai, PrECOG, and medical oncology co-chair of the NCI Renal Cancer Task Force; JIC is on speakers bureau for BMS, Merck; AA participates in advisory boards for Merck, Astra Zeneca; AA receives research funding from Clovis, Merck, BMS, Astra Zeneca, Bayer, Progenics, Janssen, Genentech, Guardant Health, Esanik, Ionnis, Prometheus; GPM declares no conflicts; BC is consultant for Eisai, Alligator, Iovance; Travel support from MedImmune Alligator; Research support from BMS, MedImmune, Prometheus, Viralytics, Galectin Therapeutics; NA is consultant to Pfizer, Novartis, Merck, Genentech, Eisai, Exelixis, Clovis, EMD Serono, BMS, Astra Zeneca, Astellas, Ely Lilly, Bayer, Pharmacyclics; RH declares no conflicts; KMM declares no conflicts; HM declares no conflicts; JT declares no conflicts; SST receives research support from Peloton, Merck, Nektar, Calithera, Jounce, Pfizer, Genetech, Prometheus, BMS; serves on advisory board for Calithera, Prometheus, BMS.; GD declares no conflicts; MAM receives research support from Merck and BMS, and honoraria from Merck; HK is an employee of Replimune, Inc.; MKKW declares no conflicts; NG is an employee of Prometheus Laboratories; DMcD is a consultant for BMS, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharm, Genentech BioOncology, Jounce and receives research funding from Prometheus Laboratories and BMS; JIC, BC, GD, MAM, MKKW, HK, DFM, JPD are unpaid members of the PROCLAIM Steering Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"84"}}